Auriga Laboratories, Inc. (OTCBB: ARGA), has announced the signing of a co-promotion agreement with MiddleBrook Pharmaceuticals, Inc., in which Auriga will co-promote Keflex ® 750mg capsules (cephalexin capsules, USP) to Primary Care Specialists in the U.S.
As the third most prescribed outpatient antibiotic in the U.S., Cephalexin (the generic form of Keflex) has approximately 25 million prescriptions written annually. It’s also the most prescribed oral cephalosporin antibiotic and the leading oral antibiotic therapy for uncomplicated skin and skin structure infections.
The co-promotion is planned to be commenced the first Quarter of 2008. Commenting on the agreement was Philip S. Pesin, CEO of Auriga, “This agreement solidifies Auriga’s commitment to enhance our product portfolio. Currently, over 50% of cephalexin prescriptions are written by Primary Care Specialists which makes Keflex® 750 mg a highly synergistic addition to Auriga’s current primary care promotional efforts.”
Auriga Laboratories is a specialty pharmaceutical company building an industry changing commission based-sales model. The business growth model outlined by the company combines driving revenues through a variable cost commission-based sales structure, acquisition of proven brand names, introduction of new brands, and a strategic development pipeline, all of which contribute to the growing relationship with physicians nationwide.
Let us hear your thoughts below: